http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 16:01:33 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Paulo+Fontoura+resigns+from+Lakefront+Biotherapeutics+board/26762401.html <p>Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced that Dr. Paulo Fontoura has resigned from its Board of Directors following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA.</p><p>Gino Santini, Chair of the Board of Directors, said: "I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board. We wish him the best of luck in his new position and we expect to appoint a successor at the earliest practical opportunity."</p><p>Lakefront Biotherapeutics, formerly known as Galapagos, is a biotechnology company based in http://www.streetinsider.com/Board+Changes/Paulo+Fontoura+resigns+from+Lakefront+Biotherapeutics+board/26762401.html Mon, 13 Jul 2026 16:01:33 -0400 LKFT http://www.streetinsider.com/Corporate+News/Paulo+Fontoura+resigns+from+Lakefront+Biotherapeutics+board/26762401.html <p>Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced that Dr. Paulo Fontoura has resigned from its Board of Directors following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA.</p><p>Gino Santini, Chair of the Board of Directors, said: "I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board. We wish him the best of luck in his new position and we expect to appoint a successor at the earliest practical opportunity."</p><p>Lakefront Biotherapeutics, formerly known as Galapagos, is a biotechnology company based in http://www.streetinsider.com/Corporate+News/Paulo+Fontoura+resigns+from+Lakefront+Biotherapeutics+board/26762401.html Mon, 13 Jul 2026 16:01:33 -0400 LKFT http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Press+Releases/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html <p align="justify"><b>Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext &amp; NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &amp; Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.</b></p> <p align="justify">“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,” said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor http://www.streetinsider.com/Globe+Newswire/Lakefront+Announces+Paulo+Fontoura+has+Resigned+from+its+Board+following+his+Appointment+as+Global+Head+of+R%26amp%3BD+at+Sanofi/26762388.html Mon, 13 Jul 2026 16:01:00 -0400 A.26729150 GLPG GLPG LKFT LKFT O.00222373 O.00832434 http://www.streetinsider.com/New+Coverage/Morgan+Stanley+Resumes+Lakefront+Biotherapeutics+%28LKFT%29+at+Equalweight/26754372.html <p>Morgan Stanley analyst Judah Frommer resumes coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Equalweight rating and a price target of $30.00.</p><p>The analyst comments: “With the recent closing of the Ouro Medicines acquisition, LKFT and GILD (covered by Terence Flynn) have acquired the rights to gamgertamig, a potential best-in-class BCMA-directed T cell engager with lower affinity for CD3, which may support a more favorable safety profile (e.g., lower CRS risk) in autoimmune conditions. LKFT/ GILD are prioritizing development in rare autoimmune indications that offer the potential for a capital-efficient unlock of blockbuster opportunities. Because of LKFT's relevant collaboration economics, gamgertamig http://www.streetinsider.com/New+Coverage/Morgan+Stanley+Resumes+Lakefront+Biotherapeutics+%28LKFT%29+at+Equalweight/26754372.html Fri, 10 Jul 2026 02:40:11 -0400 LKFT http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Resumes+Lakefront+Biotherapeutics+%28LKFT%29+at+Equalweight/26754372.html <p>Morgan Stanley analyst Judah Frommer resumes coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Equalweight rating and a price target of $30.00.</p><p>The analyst comments: “With the recent closing of the Ouro Medicines acquisition, LKFT and GILD (covered by Terence Flynn) have acquired the rights to gamgertamig, a potential best-in-class BCMA-directed T cell engager with lower affinity for CD3, which may support a more favorable safety profile (e.g., lower CRS risk) in autoimmune conditions. LKFT/ GILD are prioritizing development in rare autoimmune indications that offer the potential for a capital-efficient unlock of blockbuster opportunities. Because of LKFT's relevant collaboration economics, gamgertamig http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Resumes+Lakefront+Biotherapeutics+%28LKFT%29+at+Equalweight/26754372.html Fri, 10 Jul 2026 02:40:11 -0400 LKFT http://www.streetinsider.com/Stock+Buybacks/Lakefront+Biotherapeutics+launches+%E2%82%AC50+million+share+buyback+program/26623536.html <p>Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) announced the launch of a share repurchase program worth up to €50 million. The program allows the company to buy back ordinary shares through December 31, 2026, with Morgan Stanley & Co International PLC facilitating the transactions.</p><p>The repurchases will occur in the open market under terms approved by an Extraordinary Shareholders' Meeting held on April 28, 2026. Aaron Cox, Chief Financial Officer of Lakefront, said the program stems from a transaction with Gilead announced in March 2026, which provided the opportunity to repurchase up to $150 million of shares subject to available distributable http://www.streetinsider.com/Stock+Buybacks/Lakefront+Biotherapeutics+launches+%E2%82%AC50+million+share+buyback+program/26623536.html Tue, 09 Jun 2026 16:02:27 -0400 LKFT http://www.streetinsider.com/Corporate+News/Lakefront+Biotherapeutics+launches+%E2%82%AC50+million+share+buyback+program/26623536.html <p>Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) announced the launch of a share repurchase program worth up to €50 million. The program allows the company to buy back ordinary shares through December 31, 2026, with Morgan Stanley & Co International PLC facilitating the transactions.</p><p>The repurchases will occur in the open market under terms approved by an Extraordinary Shareholders' Meeting held on April 28, 2026. Aaron Cox, Chief Financial Officer of Lakefront, said the program stems from a transaction with Gilead announced in March 2026, which provided the opportunity to repurchase up to $150 million of shares subject to available distributable http://www.streetinsider.com/Corporate+News/Lakefront+Biotherapeutics+launches+%E2%82%AC50+million+share+buyback+program/26623536.html Tue, 09 Jun 2026 16:02:27 -0400 LKFT http://www.streetinsider.com/Corporate+News/Lakefront+Biotherapeutics+appoints+Eric+Hedrick+as+chief+medical+officer/26617169.html <p>Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) appointed Eric Hedrick as chief medical officer, the company announced. Hedrick will report to CEO Henry Gosebruch and join the management committee.</p><p>The appointment supports the company's transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. Hedrick joined Lakefront in July 2025 as clinical evaluation lead for new pipeline opportunities.</p><p>"Eric has been an invaluable contributor over this past year, driving our clinical assessments and partnering with our external colleagues," Gosebruch said. "The Ouro portfolio is now the cornerstone of Lakefront's R&D pipeline and I'm thrilled to have a talented http://www.streetinsider.com/Corporate+News/Lakefront+Biotherapeutics+appoints+Eric+Hedrick+as+chief+medical+officer/26617169.html Mon, 08 Jun 2026 16:03:24 -0400 LKFT http://www.streetinsider.com/Management+Changes/Lakefront+Biotherapeutics+appoints+Eric+Hedrick+as+chief+medical+officer/26617169.html <p>Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) appointed Eric Hedrick as chief medical officer, the company announced. Hedrick will report to CEO Henry Gosebruch and join the management committee.</p><p>The appointment supports the company's transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. Hedrick joined Lakefront in July 2025 as clinical evaluation lead for new pipeline opportunities.</p><p>"Eric has been an invaluable contributor over this past year, driving our clinical assessments and partnering with our external colleagues," Gosebruch said. "The Ouro portfolio is now the cornerstone of Lakefront's R&D pipeline and I'm thrilled to have a talented http://www.streetinsider.com/Management+Changes/Lakefront+Biotherapeutics+appoints+Eric+Hedrick+as+chief+medical+officer/26617169.html Mon, 08 Jun 2026 16:03:24 -0400 LKFT http://www.streetinsider.com/Corporate+News/Bank+of+America+crosses+5%25+threshold+in+Lakefront+Biotherapeutics/26549617.html <p>Bank of America Corporation (NYSE: BAC) has crossed above the 5% voting rights threshold in Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT), according to a transparency notification filed on May 20, 2026.</p><p>The threshold crossing occurred on May 13, 2026, following Bank of America's acquisition of voting rights and equivalent financial instruments in the biotherapeutics company. As of May 20, 2026, Bank of America and its affiliates owned 623,434 voting rights and 5,502,802 equivalent financial instruments, representing 9.30% of Lakefront's 65,897,071 outstanding shares.</p><p>The notification shows Bank of America holds 0.95% in direct voting rights and 8.35% through equivalent financial instruments. The http://www.streetinsider.com/Corporate+News/Bank+of+America+crosses+5%25+threshold+in+Lakefront+Biotherapeutics/26549617.html Tue, 26 May 2026 16:03:14 -0400 BAC LKFT http://www.streetinsider.com/Corporate+News/Bank+of+America+crosses+5%25+threshold+in+Lakefront+Biotherapeutics/26549617.html <p>Bank of America Corporation (NYSE: BAC) has crossed above the 5% voting rights threshold in Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT), according to a transparency notification filed on May 20, 2026.</p><p>The threshold crossing occurred on May 13, 2026, following Bank of America's acquisition of voting rights and equivalent financial instruments in the biotherapeutics company. As of May 20, 2026, Bank of America and its affiliates owned 623,434 voting rights and 5,502,802 equivalent financial instruments, representing 9.30% of Lakefront's 65,897,071 outstanding shares.</p><p>The notification shows Bank of America holds 0.95% in direct voting rights and 8.35% through equivalent financial instruments. The http://www.streetinsider.com/Corporate+News/Bank+of+America+crosses+5%25+threshold+in+Lakefront+Biotherapeutics/26549617.html Tue, 26 May 2026 16:03:14 -0400 BAC LKFT